A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: Superior efficacy of high daily dosage of interferon alpha in genotype 1

Journal of Viral Hepatitis

Volumn 10, Issue 3, 2003, Pages 189-196

  Tassopoulos, N C ^a   Tsantoulas, D ^b   Raptopoulou, M ^c   Vassiliadis, T ^d   Kanatakis, S ^e   Paraskevas, E ^f   Vafiadis, I ^g   Avgerinos, A ^h   Tzathas, C ^h   Manolakopoulos, S ⁱ   Ketikoglou, I ^j   Aggelis, P ^k   Goritsas, K ^k   Giannoulis, G ^l   Hatzis, G ^g   Thomopoulos, G K ^m   Akriviadis, E ^d   Sypsa, V ⁿ   Hatzakis, Angelos ⁿ  

^a Western Attica General Hospital   (Greece)

^b SISMANOGLIO HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d Aristotle University of Thessaloniki   (Greece)

^e RED CROSS HOSPITAL   (Greece)

^f Agios Savvas Cancer Hospital   (Greece)

^g LAIKO GENERAL HOSPITAL   (Greece)

^h EVANGELISMOS HOSPITAL   (Greece)

ⁱ Polikliniki Hospital   (Greece)

^j HIPPOKRATION HOSPITAL   (Greece)

^k SOTIRIA GENERAL HOSPITAL   (Greece)

^l TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^m UNIVERSITY HOSPITAL OF PATRAS   (Greece)

ⁿ UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

more..

Author keywords

Chronic hepatitis C; Daily interferon; Interferon ; Non responders; Randomized clinical trial; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSESSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID DISEASE; VIRUS LOAD; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0037715368     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00406.x     Document Type: Article

References (31)

1. World Health Organization. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1999; 49: 425-427.
2. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997; 26(3 Suppl 1): 71S-77S.
3. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
4. Reichard O. Norkrans G. Fryden A, Braconier JH. Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 83-87.
5. Poynard T. Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
6. Buti M, Esteban R. What to do when standard therapy fails. Forum (Genova) 2000; 10: 63-69
7. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 1997; 26(3 Suppl 1): 137S-142S.
8. Barbaro G. Di Lorenzo G. Belloni G et al. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after. interferon alpha therapy: a randomized trial. Am J Med 1999; 107: 112-118.
9. Sostegni R, Ghisetti V, Pittaluga F et al. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Hepatology 1998; 28: 341-346.
10. Bellobuono A. Mondazzi L. Tempini S, Silini E, Vicari F. Ideo G. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepat 1997; 4: 185-191.
11. Enriquez J. Gallego A. Torras X et al. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepat 2000; 7: 403-408.
12. Nunes DP, Anastopoulos H, Gordon F et al. Double-blind placebo controlled study of interferon versus interferon plus ribavirin for the treatment of hepatitis C in patients who previously failed interferon monotherapy. Hepatology 1999; 30: 199A.
13. Di Bisceglie AM. Thompson J, Smith-Wilkaitis N. Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001; 33: 704-707.
14. Saracco G. Ciancio A, Olivero A et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 2001: 34: 133-138.
15. Cummings KJ, Lee SM. West ES et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon. JAMA 2001; 285: 193-199.
16. Kjaergard LL, Krogsgaard K. Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 2001; 323: 1151-1155.
17. Lam NP, Neumann AU. Gretch DR, Wiley TE, Perelson AS. Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231.
18. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998: 282: 103-107.
19. Bekkering FC, Brouwer IT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in nonresponders to standard therapy. J Hepatol 1998: 28: 960-964.
20. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons, Inc. 1989.
21. Cornberg M, Jaeckel E, Schueler A et al. Treatment of chronic hepatitis C in nonresponder patients with highly daily induction dosing of interferon-alpha, ribavirin and amantadine. Hepatology 2000; 32(suppl): 351A.
22. Stanca C. Renner-Schneiter EC, Dufour JF et al. Interferon-alfa (IFN) induction dosing and ribavirin (R) in IFN non-responders (NR) with chronic hepatitis C (CHC): A multicenter trial of the Swiss Association for the Study of the Liver (SASL 10). Hepatology 2001; 34(suppl): 626.
23. de Ledinghen V, Trimoulet P, Winnock M et al. Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. J Hepatol 2002; 36: 819-826.
24. Puoti M, Cadeo GP. Putzolu V et al. Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients non responding to interferon alone. Digest Liver Dis 2000; 32: 442A.
25. Gish RG, Wakil AE. Brooks LJ, Schulze CC, Leung J. North American RibaHep Study Group. A randomized trial of daily interferon alfa-2b in combination with ribavirin vs. three times a week for one month, followed by three times a week for one year in relapse or nonresponder patients. Hepatology 1999; 30(suppl): 1132.
26. Ferenci P, Brunner H, Nachbaur K. Datz C et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001; 34: 1006-1011.
27. Zeuzem S, Feinman SV. Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
28. Manns MP. McHutchison IG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
29. Brillanti S, Levantesi F. Masi L, Foil M. Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000: 32: 630-634.
30. Adinolfi LE. Marracino M. Tonziello A et al. Interferon induction plus ribavirin and amantadine as a novel approach for treatment of interferon nonresponder chronic hepatitis C patients. Hepatology 2000; 32(suppl): 352A.
31. Cornberg M. Jaeckel E, Schueler A et al. Treatment of chronic hepatitis C in nonresponder patients with highly daily induction dosing of interferon-alpha, ribavirin and amantadine. Hepatology 2000; 32(suppl): 351A.